A plethora of new data for multiple myeloma were presented at ASCO 2022. Hear Dr. Shaji Kuman and Dr. Maria-Victoria Mateos discuss the most relevant findings and which emerging strategies look promising for patients.

In recent years, several antibody-drug conjugates (ADCs) were approved across a variety of solid tumors. This presents challenges when managing a multitude of treatment-related adverse events, some of which may lead clinicians into unfamiliar territory. This series of educational activities focuses on appropriate management of ADC-related adverse events in breast, lung, gastric, and bladder cancers.

Unexplained dyspnea may have many causes, which is why patients must have a complete diagnostic work-up to rule out pulmonary hypertension (PH) as a root cause. The differential diagnosis of PH is multifaceted and should be a collaborative effort between the community healthcare provider and the PH specialist at the PH center. Many diagnostic evaluations may be performed outside of the PH center, but right heart catheterization, which is the definitive procedure, and adjoining tests should be performed at the center. Newer and emerging diagnostic imaging techniques may also prove helpful, particularly in diagnosing chronic thromboembolism leading to chronic thromboembolic pulmonary hypertension. This program reviews the diagnostic approach to determining whether PH is the root cause of patients’ dyspnea and considers when community physicians, having created an index of suspicion for PH, should immediately refer their patients to the PH center for a full work-up.

Unexplained dyspnea may have many causes, which is why patients must have a complete diagnostic work-up to rule out pulmonary hypertension (PH) as a root cause. The differential diagnosis of PH is multifaceted and should be a collaborative effort between the community healthcare provider and the PH specialist at the PH center. Many diagnostic evaluations may be performed outside of the PH center, but right heart catheterization, which is the definitive procedure, and adjoining tests should be performed at the center. Newer and emerging diagnostic imaging techniques may also prove helpful, particularly in diagnosing chronic thromboembolism leading to chronic thromboembolic pulmonary hypertension. This program reviews the diagnostic approach to determining whether PH is the root cause of patients’ dyspnea and considers when community physicians, having created an index of suspicion for PH, should immediately refer their patients to the PH center for a full work-up.

Unexplained dyspnea may have many causes, which is why patients must have a complete diagnostic work-up to rule out pulmonary hypertension (PH) as a root cause. The differential diagnosis of PH is multifaceted and should be a collaborative effort between the community healthcare provider and the PH specialist at the PH center. Many diagnostic evaluations may be performed outside of the PH center, but right heart catheterization, which is the definitive procedure, and adjoining tests should be performed at the center. Newer and emerging diagnostic imaging techniques may also prove helpful, particularly in diagnosing chronic thromboembolism leading to chronic thromboembolic pulmonary hypertension. This program reviews the diagnostic approach to determining whether PH is the root cause of patients’ dyspnea and considers when community physicians, having created an index of suspicion for PH, should immediately refer their patients to the PH center for a full work-up.

Alzheimer’s disease (AD) is a progressive, irreversible, neurodegenerative disease that significantly impacts the lives of patients and their families, as well as society. AD is typically diagnosed later in the disease course, limiting time for psychoeducation, interventional strategies, and planning. Additionally, this delayed diagnosis leads to inefficient or unnecessary care, as well as higher costs, and causes harm to individuals and society. That is why detecting AD early is critically important.

In the second part of this two-episode series, expert faculty will answer some of your questions pertaining to the early detection of AD.

If you haven’t viewed the first part of this series, you can view it here.

Many PAH patients remain undiscovered, undiagnosed and underserved. The reasons for this are many-fold but central to the treatment of these patients is a need to make PAH care more accessible, affordable and attractive. The COVID-19 pandemic has further exacerbated the need to connect with not only undiscovered PAH patients, but even those currently under physician care. This program explores myriad aspects of finding means to discover, connect with and manage the disease of these underserved PAH patients in our general population. Key explorations brought to light in the program include the burdens many patients and physicians face with the financial costs to care, the prejudices many experience or perceive and the lack of education and awareness of patients and healthcare providers alike. Part of the solution to these modern-day issues centers on the education of physicians, reducing medical and ancillary costs to patients and making the most of the developing practices of telemedicine.

In this program, expert faculty review and discuss real-world applications of practice-changing data on the treatment of prostate cancer presented at the 2022 ASCO Genitourinary Cancers Symposium and the 2022 ASCO Annual Meeting.

In this program, expert faculty review and discuss real-world applications of practice-changing data on the treatment of prostate cancer presented at the 2022 ASCO Genitourinary Cancers Symposium and the 2022 ASCO Annual Meeting.

Many PAH patients remain undiscovered, undiagnosed and underserved. The reasons for this are many-fold but central to the treatment of these patients is a need to make PAH care more accessible, affordable and attractive. The COVID-19 pandemic has further exacerbated the need to connect with not only undiscovered PAH patients, but even those currently under physician care. This program explores myriad aspects of finding means to discover, connect with and manage the disease of these underserved PAH patients in our general population. Key explorations brought to light in the program include the burdens many patients and physicians face with the financial costs to care, the prejudices many experience or perceive and the lack of education and awareness of patients and healthcare providers alike. Part of the solution to these modern-day issues centers on the education of physicians, reducing medical and ancillary costs to patients and making the most of the developing practices of telemedicine.